Tesla
TSLA
Advanced Micro Devices
AMD
Adobe
ADBE
Broadcom
AVGO
Salesforce
CRM
US Stock MarketDetailed Quotes
AXSM Axsome Therapeutics
- 89.270
- +9.220+11.52%
Close Jan 13 16:00 ET
- 88.000
- -1.270-1.42%
Post 18:21 ET
4.33BMarket Cap-13.57P/E (TTM)
89.680High80.984Low1.88MVolume82.250Open80.050Pre Close165.87MTurnover5.19%Turnover RatioLossP/E (Static)48.46MShares105.00052wk High46.57P/B3.23BFloat Cap64.11052wk Low--Dividend TTM36.23MShs Float109.940Historical High--Div YieldTTM10.86%Amplitude1.940Historical Low88.265Avg Price1Lot Size
Axsome Therapeutics News
Axsome Therapeutics Shares Are Trading Higher After the Company Reported Preliminary Q4 and FY2024 Net Product Revenue. Additionally, Truist Securities Raised Its Price Target on the Stock From $150 to $180 While Maintaining a Buy Rating.
Needham Reiterates Buy on Axsome Therapeutics, Maintains $133 Price Target
Axsome Therapeutics: Steady Performance and Growth Potential With Key Catalysts on the Horizon
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $180
Express News | Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
Press Release: Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $180
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $140
RBC Lifts Price Target on Axsome Therapeutics to $140 From $138, Keeps Outperform Rating
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $133
Axsome Therapeutics Price Target Maintained With a $133.00/Share by Needham
Axsome Therapeutics: Strong Buy Recommendation Driven by Promising Pipeline and Market Expansion
Axsome Therapeutics Analyst Ratings
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Alzheimer's Drug Study Yields Mixed Results. Wall Street Still Likes Axsome. -- Barrons.com
Axsome Therapeutics Is Maintained at Outperform by Mizuho
Axsome Therapeutics Mixed Alzheimer's Disease Agitation Data Disappoints but Approvability Seen Likely, Mizuho Says
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.